CompletedPhase 2

Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy

Australia, Canada187 participantsStarted 2014-01-20

Plain-language summary

This study will evaluate the safety and efficacy of a range of doses of botulinum toxin Type A (BOTOX®) for the treatment of patients with bilateral Masseter Muscle Hypertrophy (MMH).

Who can participate

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓Participants with Masseter Muscle Hypertrophy

What they're measuring

Change From Baseline in Lower Facial Volume Using VECTRA 3D Images

Timeframe: Baseline (Day 1) to Day 90 of Treatment Cycle 1

Trial details

NCT IDNCT02010775

SponsorAllergan

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-03-07

Results submitted2019-02-26

View on ClinicalTrials.gov More Masseter Muscle Hypertrophy trials